Product Description
BIIB022 is a non-glycosylated human IgG4 monoclonal antibody (mAb) with specificity for IGF-1R.
Mechanisms of Action: IGF Blocker
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Hepatocellular Carcinoma|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
212-LC-101 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2011-09-01 |
|
212HC201 | P1 |
Completed |
Hepatocellular Carcinoma |
2011-04-01 |
|
212ST101 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2010-04-01 |